Evidence map›Paper›PMID 40766128›Full record

ArticlemedRxiv : the preprint server for health sciences2025

Large-scale plasma proteomics uncovers preclinical molecular signatures of Parkinson's disease and overlap with other neurodegenerative disorders.

Jan Homann, Alexander G Smith, Sarah Morgan, Elisabet A Frick, Fangyu Liu, Vivian Viallon, Rashmi Maurya, Roxanna Korologou-Linden, Valerija Dobricic, Olena Ohlei and 45 more

Abstract readPreprint
PubMed Full text at PMC Publisher
In one paragraph

Article in medRxiv : the preprint server for health sciences, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.

0numbers the graph read from it
0cells of the map it votes in
0citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

0 citing papers in PubMed.

No citing paper in PubMed yet.

4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

55 authors.

Jan HomannInstitute of Epidemiology and Social Medicine, University of Münster, Münster, Germany.
Alexander G SmithDepartment of Epidemiology and Biostatistics, School of Public Health, Imperial College London, London, UK.ORCID 0000-0001-6418-613X
Sarah MorganCentre for Neuroscience, Surgery and Trauma, Blizard Institute, Queen Mary University of London, London, UK.
Elisabet A FrickIcelandic Heart Association, Kopavogur, Iceland.
Fangyu LiuLaboratory of Behavioral Neuroscience, National Institute on Aging, Baltimore, Maryland, USA.
Vivian ViallonInternational Agency for Research on Cancer (IARC/WHO), Nutrition and Metabolism Branch, Lyon, France.
Rashmi MauryaDepartment of Psychiatry, University of Oxford, Oxford, UK.
Roxanna Korologou-LindenAgeing and Epidemiology Unit (AGE), School of Public Health, Imperial College London, London, UK.
Valerija DobricicLübeck Interdisciplinary Platform for Genome Analytics (LIGA), University of Lübeck, Lübeck, Germany.
Olena OhleiInstitute of Epidemiology and Social Medicine, University of Münster, Münster, Germany.
Laura DeeckeInstitute of Epidemiology and Social Medicine, University of Münster, Münster, Germany.
Fatema HajizadahCentre for Neuroscience, Surgery and Trauma, Blizard Institute, Queen Mary University of London, London, UK.
Yujia ZhaoInstitute for Risk Assessment Sciences, Utrecht University, Utrecht, The Netherlands.
Fanny ArtaudUniversité Paris-Saclay, UVSQ, Inserm, Gustave Roussy, CESP, Villejuif, France.
Karl Smith-ByrneCancer Epidemiology Unit, Nuffield Department of Population Health, University of Oxford, Oxford, UK.ORCID 0000-0002-1932-7463
P Martijn KolijnInstitute for Risk Assessment Sciences, Utrecht University, Utrecht, The Netherlands.
Jose Maria HuertaDepartment of Epidemiology, Murcia Regional Health Council, Biomedical Research Institute of Murcia-IMIB, Murcia, Spain.
Nils WinterInstitute of Translational Psychiatry, University of Münster, Münster, Germany.
Marcela GuevaraCentro de Investigación Biomédica en Red de Epidemiología y Salud Pública (CIBERESP), Madrid, Spain.
Ana Jimenez-ZabalaBiogipuzkoa Health Research Institute, San Sebastian, Gipuzkoa, Spain.
María José SánchezCentro de Investigación Biomédica en Red de Epidemiología y Salud Pública (CIBERESP), Madrid, Spain.
Camino Trobajo-SanmartínCentro de Investigación Biomédica en Red de Epidemiología y Salud Pública (CIBERESP), Madrid, Spain.
Natalia Cabrera-CastroDepartment of Epidemiology, Murcia Regional Health Council, Biomedical Research Institute of Murcia-IMIB, Murcia, Spain.
Ana VinagreBiogipuzkoa Health Research Institute, San Sebastian, Gipuzkoa, Spain.
Dafina PetrovaCentro de Investigación Biomédica en Red de Epidemiología y Salud Pública (CIBERESP), Madrid, Spain.
Sabina SieriEpidemiology and Prevention Unit, Fondazione IRCCS Istituto Nazionale Dei Tumori Di Milano Via Venezian, Milan, Italy.
Tim J KeyCancer Epidemiology Unit, Nuffield Department of Population Health, University of Oxford, Oxford, UK.
Nick WarehamMedical Research Council Epidemiology Unit, University of Cambridge, Cambridge, UK.
Rudolph KaaksDivision of Cancer Epidemiology, German Cancer Research Center, Heidelberg, Germany.ORCID 0000-0003-3751-3929
Ruth C TravisCancer Epidemiology Unit, Nuffield Department of Population Health, University of Oxford, Oxford, UK.
Tim HahnInstitute of Translational Psychiatry, University of Münster, Münster, Germany.
Susan BakerAgeing and Epidemiology Unit (AGE), School of Public Health, Imperial College London, London, UK.
Sean M KellyNYU Langone Health Department of Neurology.
Roel VermeulenInstitute for Risk Assessment Sciences, Utrecht University, Utrecht, The Netherlands.
Susan PetersInstitute for Risk Assessment Sciences, Utrecht University, Utrecht, The Netherlands.
Giovanna MasalaClinical Epidemiology Unit, Institute for Cancer Research, Prevention and Clinical Network (ISPRO), Florence, Italy.
Carlotta SacerdoteDepartment of Health Sciences, University of Eastern Piedmont, Novara, Italy.
Nancy FinkelNovartis, Cambridge, MA, USA.
Global Neurodegeneration Proteomics Consortium (GNPC)
Alexis ElbazUniversité Paris-Saclay, UVSQ, Inserm, Gustave Roussy, CESP, Villejuif, France.ORCID 0000-0001-9724-5490
Moritz HessInstitute of Medical Biometry and Statistics, Faculty of Medicine and Medical Center, University of Freiburg, Germany.
Verena KatzkeMedical Research Council Epidemiology Unit, University of Cambridge, Cambridge, UK.
Lars BertramLübeck Interdisciplinary Platform for Genome Analytics (LIGA), University of Lübeck, Lübeck, Germany.ORCID 0000-0002-0108-124X
Vilmundur GudnasonIcelandic Heart Association, Kopavogur, Iceland.
Oliver RobinsonDepartment of Epidemiology and Biostatistics, School of Public Health, Imperial College London, London, UK.
Honglei ChenDepartment of Epidemiology and Biostatistics, Michigan State University, East Lansing, Michigan, USA.
Lefkos MiddletonAgeing and Epidemiology Unit (AGE), School of Public Health, Imperial College London, London, UK.
Laura M WinchesterDepartment of Psychiatry, University of Oxford, Oxford, UK.ORCID 0000-0003-3826-7694
Ioanna TzoulakiDepartment of Epidemiology and Biostatistics, School of Public Health, Imperial College London, London, UK.ORCID 0000-0002-4275-9328
Valborg GudmundsdottirIcelandic Heart Association, Kopavogur, Iceland.
Keenan A WalkerLaboratory of Behavioral Neuroscience, National Institute on Aging, Baltimore, Maryland, USA.ORCID 0000-0002-5989-9853
Pietro FerrariInternational Agency for Research on Cancer (IARC/WHO), Nutrition and Metabolism Branch, Lyon, France.
Elio RiboliDepartment of Epidemiology and Biostatistics, School of Public Health, Imperial College London, London, UK.
Marc J GunterDepartment of Epidemiology and Biostatistics, School of Public Health, Imperial College London, London, UK.
Christina M LillInstitute of Epidemiology and Social Medicine, University of Münster, Münster, Germany.

Funding

ARIC Neurocognitive Study (ARIC-NCS) Renewal 2023-2028U01HL096812 · NHLBI · NEW YORK UNIVERSITY SCHOOL OF MEDICINE · PI JOSEF CORESH, THOMAS H MOSLEY · 2010 to 2026
$65.7M
Uncovering new genes and disease modifiers for ALS and related disordersU54NS092091 · NINDS · UNIVERSITY OF MIAMI SCHOOL OF MEDICINE · PI Corey T McMillan · 2014 to 2026
$19.8M
THE ATHEROSCLEROSIS RISK IN COMMUNITIES (ARIC) STUDY - COORDINATING CENTER - TASK AREA B.2 AND B.375N92022D00001 · NHLBI · UNIV OF NORTH CAROLINA CHAPEL HILL · PI COUPER, DAVID · 2022 to 2025
$13.7M
ARIC Neurocognitive Study (ARIC-NCS) Renewal 2 of 5U01HL096917 · NHLBI · UNIVERSITY OF MISSISSIPPI MED CTR · PI MOSLEY, THOMAS H · 2010 to 2018
$11.9M
ARIC Neurocognitive Study (ARIC-NCS) Renewal UNC 4 of 5U01HL096899 · NHLBI · UNIV OF NORTH CAROLINA CHAPEL HILL · PI COUPER, DAVID J · 2010 to 2018
$7.5M
ARIC Neurocognitive Study (ARIC-NCS)U01HL096902 · NHLBI · UNIVERSITY OF MINNESOTA · PI LUTSEY, PAMELA L. · 2010 to 2018
$7.4M
ARIC Neurocognitive Study (ARIC-NCS) Renewal 4 of 5U01HL096814 · NHLBI · WAKE FOREST UNIVERSITY HEALTH SCIENCES · PI HUGHES, TIMOTHY M., WAGENKNECHT, LYNNE E · 2010 to 2018
$6.5M
THE ATHEROSCLEROSIS RISK IN COMMUNITIES (ARIC) STUDY - FIELD CENTER - TASK ORDER 01, TASK AREA A75N92022D00003 · NHLBI · UNIVERSITY OF MINNESOTA · PI LUTSEY, PAMELA · 2022 to 2025
$5.1M
THE ATHEROSCLEROSIS RISK IN COMMUNITIES (ARIC) STUDY - FIELD CENTER - TASK ORDER 01, TASK AREA A75N92022D00005 · NHLBI · WAKE FOREST UNIVERSITY HEALTH SCIENCES · PI WAGENKNECHT, LYNNE · 2022 to 2025
$5.0M
THE ATHEROSCLEROSIS RISK IN COMMUNITIES (ARIC) STUDY - FIELD CENTER - TASK ORDER 01, TASK AREA A75N92022D00004 · NHLBI · UNIVERSITY OF MISSISSIPPI MED CTR · PI WINDHAM, BEVERLY GWEN · 2022 to 2025
$4.8M
THE ATHEROSCLEROSIS RISK IN COMMUNITIES (ARIC) STUDY - FIELD CENTER - TASK ORDER 01, TASK AREA A75N92022D00002 · NHLBI · JOHNS HOPKINS UNIVERSITY · PI CORESH, JOSEF · 2022 to 2025
$4.7M
Serum proteome analysis of Alzheimer´s disease in a population-based longitudinal cohort study - the AGES Reykjavik studyR01AG065596 · NIA · ICELANDIC HEART ASSOCIATION · PI Valborg Gudmundsdottir · 2021 to 2026
$2.6M
NHLBI NIH HHS 75N92022D00001NHLBI NIH HHS 75N92022D00002NHLBI NIH HHS 75N92022D00003NHLBI NIH HHS 75N92022D00004NHLBI NIH HHS 75N92022D00005NHLBI NIH HHS U01 HL096812NHLBI NIH HHS U01 HL096814NHLBI NIH HHS U01 HL096899NHLBI NIH HHS U01 HL096902NHLBI NIH HHS U01 HL096917NIA NIH HHS N01 AG012100NIA NIH HHS R01 AG065596NINDS NIH HHS U54 NS092091
6 · The paper itself

Abstract

Parkinson's disease (PD) remains incurable, with a long preclinical phase currently undetectable by existing methods. In the largest proteomic study in neurodegenerative diseases to date, we analyzed blood samples from ~74,000 individuals across discovery and validation cohorts. In the EPIC4PD discovery case-cohort, large-scale profiling of 7,285 proteins (SomaScan-7K) in 4,538 initially unaffected participants (574 incident cases) identified 17 proteins that predict PD up to 28 years before diagnosis. Additional proteins revealed sex-specific effects and time-dependent effect trajectories, capturing disease progression before symptom onset. Replication in three prospective cohorts (n=64,856; 1,034 incident cases) confirmed at least 12 key pre-diagnostic biomarkers with strong evidence, including TPPP2, HPGDS, ALPL, MFAP5, OGFR, ACAD8, TCL1A, GPC4, GSTA3, LCN2, KRAS, and GJA1. Preclinical biomarkers showed 86% concordant effect directions in independent prevalent PD cases (n=2,592; p=1.6×10

Indexed as

aptamersEPICneurodegenerationParkinson’s diseasepredictionprotein risk scoreproteomicsSomaLogic

Identifiers

PMID40766128
PMCPMC12324616

What OpenQuestion holds

Textmetadata
LicenceCC BY-NC-ND
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.